The indications, efficacy and adverse events of rituximab in a large cohort of patients with juvenile-onset SLE

Lupus

Volumn 24, Issue 1, 2015, Pages 10-17

  Watson, L ^a,b   Beresford, M W ^a,b   Maynes, C ^c   Pilkington, C ^c   Marks, S D ^c   Glackin, Y ^c   Tullus, K ^c  

^a UNIVERSITY OF LIVERPOOL   (United Kingdom)

^b ALDER HEY CHILDREN'S NHS FOUNDATION TRUST   (United Kingdom)

^c GREAT ORMOND STREET HOSPITAL   (United Kingdom)

Author keywords

B cell depletion; child; lupus; Rituximab; SLE

Indexed keywords

ALBUMIN; AZATHIOPRINE; COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOUBLE STRANDED DNA ANTIBODY; ETANERCEPT; HEMOGLOBIN; IMMUNOGLOBULIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; TACROLIMUS; THALIDOMIDE; TOCILIZUMAB; ANTINUCLEAR ANTIBODY; BIOLOGICAL MARKER; DNA; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; SERUM ALBUMIN;

ACUTE KIDNEY FAILURE; ADENOVIRUS INFECTION; ADOLESCENT; ALLERGIC REACTION; ARTHRALGIA; ARTHRITIS; ARTICLE; BONE PAIN; BRAIN DISEASE; CHILD; CLINICAL FEATURE; CONTROLLED STUDY; CYTOMEGALOVIRUS INFECTION; DISEASE ACTIVITY; DISEASE MARKER; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG INDICATION; DRUG USE; ERYTHROCYTE SEDIMENTATION RATE; ESOPHAGUS STENOSIS; ETHNIC GROUP; FEMALE; FEVER; GASTROINTESTINAL DISEASE; GROWTH DISORDER; HEART DISEASE; HEMODIALYSIS; HEMOGLOBIN DETERMINATION; HERPES ZOSTER; HUMAN; HUMORAL IMMUNE DEFICIENCY; IMMUNOSUPPRESSIVE TREATMENT; JUVENILE ONSET SYSTEMIC LUPUS ERYTHEMATOSUS; KIDNEY DISEASE; LETHARGY; LEUKOCYTE COUNT; LUPUS ERYTHEMATOSUS NEPHRITIS; MAJOR CLINICAL STUDY; MALAISE; MALE; MICROSCOPIC PROTEINURIA; NEPHROTIC SYNDROME; NEUTROPENIA; PANCREATITIS; PLASMAPHERESIS; PLEURA EFFUSION; PROTEINURIA; RASH; REMISSION; SKIN DISEASE; SYSTEMIC DISEASE; SYSTEMIC LUPUS ERYTHEMATOSUS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; UPPER RESPIRATORY TRACT INFECTION; URINE; URINE ALBUMIN CREATININE RATIO; VASCULITIS; ALBUMINURIA; B LYMPHOCYTE; BLOOD; IMMUNOLOGY; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE COUNT; METABOLISM; RETROSPECTIVE STUDY;

ADOLESCENT; ADRENAL CORTEX HORMONES; ALBUMINURIA; ANTIBODIES, ANTINUCLEAR; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; B-LYMPHOCYTES; BIOMARKERS; BLOOD SEDIMENTATION; CHILD; COMPLEMENT C3; COMPLEMENT C4; CREATININE; DNA; FEMALE; HEMOGLOBINS; HUMANS; IMMUNOGLOBULINS; IMMUNOLOGIC FACTORS; LUPUS ERYTHEMATOSUS, SYSTEMIC; LYMPHOCYTE COUNT; MALE; RETROSPECTIVE STUDIES; RITUXIMAB; SERUM ALBUMIN;

EID: 84918589927     PISSN: 09612033     EISSN: 14770962     Source Type: Journal    
DOI: 10.1177/0961203314547793     Document Type: Article

References (25)

1. Singer NG, Scalzi LV. Remittive agents in pediatric rheumatology. Curr Opin Rheumatol. 2004 ; 16: 571-576
2. Iwata S, Saito K, Tokunaga M, et al. Phenotypic changes of lymphocytes in patients with systemic lupus erythematosus who are in longterm remission after B cell depletion therapy with rituximab. J Rheumatol. 2011 ; 38: 633-641
3. Morgan TA, Watson L, McCann LJ, Beresford MW. Children and adolescents with SLE: Not just little adults. Lupus. 2013 ; 22: 1309-1319
4. Tucker LB, Uribe AG, Fernández M, et al. Adolescent onset of lupus results in more aggressive disease and worse outcomes: Results of a nested matched case-control study within LUMINA, a multiethnic US cohort (LUMINA LVII). Lupus. 2008 ; 17: 314-322
5. Watson L, Leone V, Pilkington C, et al. Disease activity, severity, and damage in the UK Juvenile-Onset Systemic Lupus Erythematosus Cohort. Arthritis Rheum. 2012 ; 64: 2356-2365
6. Witt M, Grunke M, Proft F, et al. Clinical outcomes and safety of rituximab treatment for patients with systemic lupus erythematosus (SLE) - results from a nationwide cohort in Germany (GRAID). Lupus. 2013 ; 22: 1142-1149
7. Diaz-Lagares C, Croca S, Sangle S, et al. Efficacy of rituximab in 164 patients with biopsy-proven lupus nephritis: Pooled data from European cohorts. Autoimmun Rev. 2012 ; 11: 357-364
8. Terrier B, Amoura Z, Ravaud P, et al. Safety and efficacy of rituximab in systemic lupus erythematosus: Results from 136 patients from the French AutoImmunity and Rituximab registry. Arthritis Rheum. 2010 ; 62: 2458-2466
9. Rovin BH, Furie R, Latinis K, et al. Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: The Lupus Nephritis Assessment with Rituximab (LUNAR) study. Arthritis Rheum. 2012 ; 64: 1215-1226
10. Merrill JT, Neuwelt CM, Wallace DJ, et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: The randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial. Arthritis Rheum. 2010 ; 62: 222-233
11. Murray E, Perry M. Off-label use of rituximab in systemic lupus erythematosus: A systematic review. Clin Rheumatol. 2010 ; 29: 707-716
12. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum. 1997 ; 40: 1725-1725
13. Watson L, Leone V, Pilkington C, et al. Juvenile-onset SLE; disease activity, severity and damage - the UK JSLE Cohort Study. Arthritis Rheum. 2012 ; 64: 2356-2365
14. Isenberg DA, Rahman A, Allen E, et al. BILAG 2004. Development and initial validation of an updated version of the British Isles Lupus Assessment Group's disease activity index for patients with systemic lupus erythematosus. Rheumatology (Oxford). 2005 ; 44: 902-906
15. Edwards IR, Aronson JK. Adverse drug reactions: Definitions, diagnosis, and management. Lancet. 2000 ; 356: 1255-1259
16. British Society for Paediatric and Adolescent Rheumatology. BSPAR guidance for rituximab, http://wwwbspar.org.uk/clinical-guidelines (accessed 16 December 2013).
17. Marks SD, Patey S, Brogan PA, et al. B lymphocyte depletion therapy in children with refractory systemic lupus erythematosus. Arthritis Rheum. 2005 ; 52: 3168-3174
18. Md Yusof MY, Vital EM, Emery P. B-cell-targeted therapies in systemic lupus erythematosus and ANCA-associated vasculitis: Current progress. Expert Rev Clin Immunol. 2013 ; 9: 761-772
19. Hui M, Garner R, Rees F, et al. Lupus nephritis: A 15-year multi-centre experience in the UK. Lupus. 2013 ; 22: 328-332
20. Butterly SJ, Pillans P, Horn B, Miles R, Sturtevant J. Off-label use of rituximab in a tertiary Queensland hospital. Intern Med J. 2010 ; 40: 443-452
21. Marks SD, Tullus K. Modern therapeutic strategies for paediatric systemic lupus erythematosus and lupus nephritis. Acta Paediatr. 2010 ; 99: 967-974
22. Brunner HI, Gladman DD, Ibañez D, Urowitz MD, Silverman ED. Difference in disease features between childhood-onset and adult-onset systemic lupus erythematosus. Arthritis Rheum. 2008 ; 58: 556-562
23. Can M, Alibaz-Öner F, Yilmaz-Öner S, Atagündüz P, Inanç N, Direskeneli H. Accelerated infusion rates of rituximab are well tolerated and safe in rheumatology practice: A single-centre experience. Clin Rheumatol. 2013 ; 32: 87-90
24. Conti F, Ceccarelli F, Perricone C, et al. Rituximab infusion-related adverse event rates are lower in patients with systemic lupus erythematosus than in those with rheumatoid arthritis. Rheumatology (Oxford). 2011 ; 50: 1148-1152
25. Fernández-Nebro A, de la Fuente JL, Carreño L, et al. Multicenter longitudinal study of B-lymphocyte depletion in refractory systemic lupus erythematosus: The LESIMAB study. Lupus. 2012 ; 21: 1063-1076